EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations

Katherine E R Smith iD, Aldo A Acosta-Medina, Surendra Dasari, Wasantha Ranatunga, Karen L Rech iD, Aishwarya Ravindran, Jason R Young, Patrick W McGarrah iD, Gordon J Ruan iD, Saurabh S Zanwar iD, Jenny J Li, Julio C Sartori-Valinotti und 5 weitere

JCO Precision Oncology · 2024

DOI: 10.1200/po-24-00471 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Katherine E R Smith und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Precision Medicine, Erdheim-Chester Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE BRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making these treatments less effective. METHODS We describe three patients with histiocytic disorders who have novel non-MAPK pathway alterations. These alterations were studied through genomic and in silico analyses when applicable, then treated with off-label medications rationally selected on the basis of genomic alterations. RESULTS Patient 1 had rapidly progressive ECD involving the CNS. A CSF1R in-frame deletion (p.S560_P566del) was identified, and in silico modeling predicted a gain-of-function mutation. This alteration was targeted with pexidartinib, which led to a clinical complete response (CR) within 2 months, and a partial response (PR) on imaging after 3 months. After 15 months, the disease became resistant to pexidartinib and transformed to histiocytic sarcoma. Patient 2 has skin-only involvement of a xanthogranuloma disorder. A KIF5B-FGFR1 fusion was identified on RNA sequencing and targeted with pemigatinib. At 24 months of follow-up, she remains in a clinical PR. Patient 3 has ECD involving the bone marrow, gastrointestinal tract, and subcutaneous tissues. A MEF2C-FLT3 fusion was identified and targeted with sorafenib. He achieved a clinical CR and radiographic PR within 3 months, which has continued for 30 months. CONCLUSION We report three patients with histiocytic disorders harboring novel alterations who had sustained responses to off-label kinase inhibitors specific to their histiocytic disorder. Pathogenic variants outside of the MAPK pathway, including variants of unknown significant, may be targeted with readily available small molecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineErdheim-Chester DiseaseHumansMaleFemaleMiddle AgedAdultAminopyridinesHistiocytosisProtein Kinase InhibitorsPyrrolesReceptor, Macrophage Colony-Stimulating Factor

Substanzen

pexidartinibCSF1R protein, humanAminopyridinesProtein Kinase InhibitorsPyrrolesReceptor, Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Hematology, Mayo Clinic, Rochester, MN.
  • Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Department of Hematopathology, Mayo Clinic, Rochester, MN.
  • Department of Radiology, Mayo Clinic, Jacksonville, FL.
  • Department of Dermatology, Mayo Clinic, Rochester, MN.
  • Mercy Clinic Cancer and Hematology, Chub O'Reilly Cancer Center, Springfield, MO.

ORCID-Profile: Katherine E R Smith, Karen L Rech, Patrick W McGarrah, Gordon J Ruan, Saurabh S Zanwar, Thomas E Witzig, Gaurav Goyal, Ronald S Go, Jithma P Abeykoon

Zitieren

APA

Smith, K. E. R., Acosta-Medina, A. A., Dasari, S., Ranatunga, W., Rech, K. L., Ravindran, A., Young, J. R., McGarrah, P. W., Ruan, G. J., Zanwar, S. S., Li, J. J., Sartori-Valinotti, J. C., Snider, J. N., Witzig, T. E., Goyal, G., Go, R. S., & Abeykoon, J. P. (2024). Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations. JCO Precision Oncology. https://doi.org/10.1200/po-24-00471

Vancouver

Smith KER, Acosta-Medina AA, Dasari S, Ranatunga W, Rech KL, Ravindran A, et al. Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations. JCO Precision Oncology. 2024. doi:10.1200/po-24-00471

BibTeX
@article{Smith2024,
  author = {Smith, Katherine E R and Acosta-Medina, Aldo A and Dasari, Surendra and Ranatunga, Wasantha and Rech, Karen L and Ravindran, Aishwarya and Young, Jason R and McGarrah, Patrick W and Ruan, Gordon J and Zanwar, Saurabh S and Li, Jenny J and Sartori-Valinotti, Julio C and Snider, Jessica N and Witzig, Thomas E and Goyal, Gaurav and Go, Ronald S and Abeykoon, Jithma P},
  title = {Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po-24-00471}
}
Kostenlos starten →